DEXAspheres (dexamethasone microspheres) / Regeneron - LARVOL DELTA

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=3 | Completed | Sponsor: Oxular Limited | Active, not recruiting ➔ Completed

Trial completion • Diabetic Macular Edema • Ophthalmology

3D-printed scaffolds: Incorporating dexamethasone microspheres and BMP2 for enhanced osteogenic differentiation of human mesenchymal stem cells. (PubMed, Colloids Surf B Biointerfaces) - "Calcium deposition and elemental analysis also demonstrated enhanced mineralization in the Dex-M+BMP2 +G-scaffold group, with calcium and phosphate levels 3.9-1.7 times higher than in the other groups. Overall, the Dex-M+BMP2 +G-scaffold effectively promoted osteogenic differentiation and mineralization of hMSCs, underscoring its potential as a promising biomaterial for bone tissue engineering applications."

Journal • BMP2

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=3 | Active, not recruiting | Sponsor: Oxular Limited | Recruiting ➔ Active, not recruiting | N=128 ➔ 3 | Trial primary completion date: Sep 2024 ➔ Nov 2024

Enrollment change • Enrollment closed • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=128 | Recruiting | Sponsor: Oxular Limited | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2023 ➔ Jul 2023

Enrollment open • Trial initiation date • Diabetic Macular Edema • Ophthalmology

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=128 | Not yet recruiting | Sponsor: Oxular Limited

New P2 trial • Diabetic Macular Edema • Ophthalmology